MAIA Biotechnology (NYSE: MAIA) files new investor presentation 8-K

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. filed a current report describing new investor presentation materials that its management plans to use from time to time, including at the Biotech Showcase conference in San Francisco, California on January 13, 2026. The presentation materials are included as Exhibit 99.1 and were also posted on the company’s website on January 13, 2026.

The company notes that the presentation materials contain forward-looking statements, emphasizing that readers and investors should be cautious in placing reliance on these statements. The filing is made as a Regulation FD disclosure and an “Other Events” update, with no separate financial results or major transactions described.

false 0001878313 0001878313 2026-01-13 2026-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700 Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

MAIA Biotechnology, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that its management intends to use from time to time, including at the Biotech Showcase in San Francisco, California on January 13, 2026. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K. In addition, the Company posted the Presentation Materials on its website (www.maiabiotech.com) on January 13, 2026.

The Presentation Materials contain forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements.

Item 8.01 Other Events

Reference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation Materials
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 13, 2026

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3

FAQ

What did MAIA (MAIA) disclose in this 8-K filing?

The report explains that MAIA Biotechnology, Inc. prepared investor presentation materials that its management may use from time to time, including at the Biotech Showcase in San Francisco on January 13, 2026, and that these materials are filed as Exhibit 99.1 and posted on the company’s website.

What are the presentation materials mentioned by MAIA (MAIA)?

The presentation materials are a slide deck or similar investor presentation that MAIA Biotechnology’s management intends to use with investors and at events; they are identified as Exhibit 99.1 and form part of the information provided in this report.

Where can investors find MAIA Biotechnology’s presentation materials?

The filing states that the presentation materials are attached as Exhibit 99.1 and were also posted on MAIA Biotechnology’s website at www.maiabiotech.com on January 13, 2026.

Does MAIA’s 8-K include new financial results or earnings data?

The report is focused on Regulation FD disclosure of presentation materials and lists them as an exhibit; it does not describe separate financial statements or detailed earnings data within the text provided.

Why does MAIA mention forward-looking statements in the presentation?

MAIA Biotechnology notes that the presentation materials contain forward-looking statements and cautions that investors should not place undue reliance on these statements, highlighting the usual uncertainties associated with projections and expectations.

What exhibits are attached to MAIA Biotechnology’s 8-K?

The filing lists Exhibit 99.1 as the presentation materials and notes that Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.